Related Experiment Videos
Drug therapy of neurovascular disease
Jesse Weinberger1, William H Frishman, Dawn Terashita
1Department of Neurology, Mt. Sinai Medical Center, New York, New York, USA. jesswein@pol.net
Insights
Effective stroke prevention and treatment involve early thrombolytic therapy for ischemic stroke and specific medications for secondary prevention. Primary prevention through managing hypertension and high cholesterol is crucial for better cerebrovascular disease outcomes.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Pharmacotherapy
Background:
- Cerebrovascular disease management has advanced, improving patient outcomes.
- Early interventions are key for both acute stroke treatment and secondary prevention.
Purpose of the Study:
- To review recent advances in the prevention and pharmacotherapy of cerebrovascular disease.
- To highlight effective strategies for acute stroke, secondary prevention, and primary prevention.
Main Methods:
- Review of current pharmacotherapies and treatment strategies.
- Analysis of clinical outcomes associated with various interventions.
Main Results:
- Early thrombolytic agents improve outcomes in acute ischemic stroke.
- Antiplatelet drugs, statins, and ACE inhibitors reduce secondary stroke events.
- Warfarin is recommended for stroke prevention in patients with atrial fibrillation or heart disease.
- Calcium channel blockers may improve outcomes in hemorrhagic stroke.
- Innovative therapies exist for migraine and vascular dementia.
Conclusions:
- Primary prevention, including managing hypertension and hypercholesterolemia, is the optimal strategy.
- Pharmacotherapy plays a vital role in both acute stroke management and long-term prevention.
- Tailored treatment approaches are necessary for different types of cerebrovascular events.
Abstract:
Recent advances in the prevention and pharmacotherapy of cerebrovascular disease have provided more favorable clinical outcomes. For the treatment of an acute ischemic stroke, the early use of thrombolytic agents can reduce the degree of brain damage while improving functional outcomes. However, trials evaluating various classes of other neuroprotective agents have not shown benefit to date. For the prevention of second stroke, the use of antiplatelet drugs, HMG-CoA reductase inhibitors, and angiotensin-converting enzyme inhibitors with a diuretic have shown benefit in reducing new events. In patients with underlying heart disease or atrial fibrillation, warfarin appears to be the drug of choice in preventing stroke. Early treatment of hemorrhagic stroke with calcium channel blockers can improve the functional outcome. Innovative therapies are now available for the treatment of migraine and vascular dementia. Primary prevention of stroke remains the optimal therapeutic strategy and includes treatment of systemic hypertension and hypercholesterolemia.